It was reported that, through the study of 225 newly-diagnosed multiple myeloma patients, patients harboring more CD81+ in tumor cell plasma had a less differentiation state, dismal survival, and higher chemoresistance [21]. Here, CD81 is linked to plasma cell myeloma.